These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1479 related items for PubMed ID: 26910388

  • 21. Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.
    Kowalczyk M, Rubinstein PG, Aboulafia DM.
    J Int Assoc Provid AIDS Care; 2015; 14(3):211-6. PubMed ID: 25504472
    [Abstract] [Full Text] [Related]

  • 22. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G, Palladino V, Vecchio GCD, Palmieri VV, Corallo PC, Faienza MF, Giordano P.
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
    [Abstract] [Full Text] [Related]

  • 23. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
    Meyer O, Salama A.
    Onkologie; 2011; 34(1-2):10-3. PubMed ID: 21346379
    [Abstract] [Full Text] [Related]

  • 24. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S, Nakaseko C, Takeuchi M, Kumagai K, Komatsu T, Tanaka H, Hara S, Koizumi M, Imai H, Yokota A, Takeuchi M, Inokuchi K, Matsuura Y, Aotsuka N, Wakita H.
    Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
    [No Abstract] [Full Text] [Related]

  • 25. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study.
    Michel M, Ruggeri M, Gonzalez-Lopez TJ, Alkindi S, Cheze S, Ghanima W, Tvedt THA, Ebbo M, Terriou L, Bussel JB, Godeau B.
    Blood; 2020 Dec 24; 136(26):3056-3061. PubMed ID: 32814348
    [Abstract] [Full Text] [Related]

  • 26. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia.
    Khellaf M, Viallard JF, Hamidou M, Cheze S, Roudot-Thoraval F, Lefrere F, Fain O, Audia S, Abgrall JF, Michot JM, Dauriac C, Lefort S, Gyan E, Niault M, Durand JM, Languille L, Boutboul D, Bierling P, Michel M, Godeau B.
    Haematologica; 2013 Jun 24; 98(6):881-7. PubMed ID: 23445876
    [Abstract] [Full Text] [Related]

  • 27. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.
    Gudbrandsdottir S, Frederiksen H, Hasselbalch H.
    Platelets; 2012 Jun 24; 23(6):423-9. PubMed ID: 22185370
    [Abstract] [Full Text] [Related]

  • 28. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura.
    Zeng Y, Duan X, Xu J, Ni X.
    Cochrane Database Syst Rev; 2011 Jul 06; 2011(7):CD008235. PubMed ID: 21735426
    [Abstract] [Full Text] [Related]

  • 29. Is ITP a thrombophilic disorder?
    Rodeghiero F.
    Am J Hematol; 2016 Jan 06; 91(1):39-45. PubMed ID: 26547507
    [Abstract] [Full Text] [Related]

  • 30. Thrombopoietin receptor agonists in hereditary thrombocytopenias.
    Rodeghiero F, Pecci A, Balduini CL.
    J Thromb Haemost; 2018 Sep 06; 16(9):1700-1710. PubMed ID: 29956472
    [Abstract] [Full Text] [Related]

  • 31. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
    Makar RS, Zhukov OS, Sahud MA, Kuter DJ.
    Am J Hematol; 2013 Dec 06; 88(12):1041-4. PubMed ID: 23913253
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
    Zeller MP, Heddle NM, Kelton JG, Hamilton K, Wang G, Sholapur N, Carruthers J, Hsia C, Blais N, Toltl L, Hamm C, Pearson MA, Arnold DM.
    Transfusion; 2016 Jan 06; 56(1):73-9. PubMed ID: 26400824
    [Abstract] [Full Text] [Related]

  • 35. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
    Iino M, Sakamoto Y, Sato T.
    Int J Hematol; 2020 Aug 06; 112(2):159-168. PubMed ID: 32476083
    [Abstract] [Full Text] [Related]

  • 36. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
    Zhang J, Liang Y, Ai Y, Xie J, Li Y, Zheng W.
    Expert Opin Pharmacother; 2017 Oct 06; 18(15):1543-1551. PubMed ID: 28845713
    [Abstract] [Full Text] [Related]

  • 37. Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience.
    Özdemirkıran F, Payzın B, Kiper HD, Kabukçu S, Akgün Çağlıyan G, Kahraman S, Sevindik ÖG, Ceylan C, Kadıköylü G, Şahin F, Keskin A, Arslan Ö, Özcan MA, Kabukçu G, Görgün G, Bolaman Z, Büyükkeçeci F, Bilgir O, Alacacıoğlu İ, Vural F, Tombuloğlu M, Gökgöz Z, Saydam G.
    Turk J Haematol; 2015 Dec 06; 32(4):323-8. PubMed ID: 25914025
    [Abstract] [Full Text] [Related]

  • 38. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy.
    Mitsuhashi K, Ishiyama M, Imai Y, Shiseki M, Mori N, Teramura M, Seshimo A, Motoji T.
    Br J Haematol; 2012 Sep 06; 158(6):798-800. PubMed ID: 22758388
    [No Abstract] [Full Text] [Related]

  • 39. Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice.
    Depré F, Aboud N, Mayer B, Salama A.
    PLoS One; 2018 Sep 06; 13(6):e0198184. PubMed ID: 29856800
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 74.